Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Alastair Smith, Avacta Group CEO gives an Operational Update


Astrazeneca Share Price (AZN)



Share Price Information for Astrazeneca (AZN)


Share Price: 5,652.00Bid: 5,666.00Ask: 5,668.00Change: 0.00 (0.00%)No Movement on Astrazeneca
Spread: 2.00Spread as %: 0.04%Open: 5,670.00High: 5,697.00Low: 5,633.00Yesterday’s Close: 5,652.00

Astrazeneca Plc Ord Shs $0.25

Astrazeneca is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Astrazeneca is part of the Medicine and Biotech Research sector

Global Pharmaceutical company with 6700 employees across 7 sites in the UK. AstraZeneca work with the NHS, UK healthcare professionals, government and policy makers and patient groups. Market cap £65.05bn.





Share Price SpacerPrice
5652.00
Share Price SpacerBid
5666.00
Share Price SpacerAsk
5668.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
978,485
Share Price SpacerOpen
5,670.00
Share Price SpacerHigh
5,697.00
Share Price SpacerLow
5,633.00
Share Price SpacerClose
5,652.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 1,266.78m £71,598.38m 300

52 Week High 6,122.00 52 Week High Date 10-AUG-2018
52 Week Low 4,544.50 52 Week Low Date 6-FEB-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
5,412 616,231 280,252 32.051 176.34 219.10 3.88


London South East Users info for Astrazeneca




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

24-Sep-18
17:09:22
5,652.00
48,224
Sell* 
5,666.00
5,668.00
2.726M
Trade Type:
Ordinary
Delayed publication

24-Sep-18
17:08:22
5,652.00
29,325
Sell* 
5,666.00
5,668.00
1.657M
Trade Type:
Ordinary
Delayed publication

24-Sep-18
17:31:24
5,652.00
28,840
Sell* 
5,666.00
5,668.00
1.630M
Trade Type:
Ordinary
Delayed publication




View more Astrazeneca trades >>

Directors Deals for Astrazeneca (AZN)
Trade DateActionNotifierPriceCurrencyAmountHolding
27-Jul-17Buy
Trade Notifier Information for AstraZeneca
Nazneen Rahman held the position of Non-Executive Director at AstraZeneca at the time of this trade.
 Nazneen Rahman
4335.48GBX46139
27-Jul-17Buy
Trade Notifier Information for AstraZeneca
Philip A J Broadley held the position of Non-Executive Director at AstraZeneca at the time of this trade.
 Philip A J Broadley
4282GBX2,3000
27-Jul-17Buy
Trade Notifier Information for AstraZeneca
Nazneen Rahman held the position of Non-Executive Director at AstraZeneca at the time of this trade.
 Nazneen Rahman
4370.13GBX3939
View more Astrazeneca directors dealings >>


easyp
Posts: 1,241
Opinion:No Opinion
Price:5,589.00
RE: Fraid I took the money
18 Sep '18
I have purchased and sold a couple of times over the past 5 years and made a little money while others have held for the dividend and relative safety of AZ.

I am tempted to buy back in after a good run with OXB but fear that Trump will come after big Pharma in the USA over drug prices. So while the AZ drug pipeline look good I am going to sit on my hands for a while longer. To those that have bought and held over three years the possibility of a dip in sp related to drug pricing is not a big issue for someone looking to time an entry it is.
driftking27
Posts: 1,408
Opinion:Hold
Price:5,645.00
RE: The Lid has been lifted
14 Sep '18
The reason that rose on ex-dividend was due to the $ weakened and thus the sp rose.

This is the most likeliest reasons
Inkose
Posts: 10
Opinion:No Opinion
Price:5,596.00
FDA OKs AstraZeneca's Lumoxiti for
14 Sep '18
Sep. 13, 2018 2:17 PM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
The FDA approves AstraZeneca's (AZN -1.1%) Lumoxiti (moxetumomab pasudotox-tdfk) injection for the treatment of adult patients with relapsed/refractory hairy cell leukemia (HCL) who have received at least two prior lines of systemic therapies, including a purine nucleoside analog.

Orphan Drug-tagged Lumoxiti is an anti-CD22 recombinant immunotoxin. It consists of an antibody that binds to protein found on B-lymphocytes (CD22) that is fused to a toxin. Once the molecule is internalized by the cancer cell, the toxin leads to cell death by inhibiting protein translation. Specifically, the cell cannot read the information from messenger RNA so it cannot build proteins and dies.
Inkose
Posts: 10
Opinion:No Opinion
Price:5,886.00
AstraZeneca's Lynparza OK'd in Chin
24 Aug '18
Aug. 24, 2018 7:43 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
The China National Drug Administration has approved AstraZeneca's (NYSE:AZN) LYNPARZA (olaparib) for the maintenance treatment of recurrent platinum-sensitive ovarian cancer, the first targeted therapy approved there for the indication.

The company is co-developing the PARP inhibitor with Merck (NYSE:MRK).
Inkose
Posts: 10
Opinion:No Opinion
Price:5,883.00
AstraZeneca says lung-disease treat
24 Aug '18
AstraZeneca said Wednesday results from a recent study showed its drug to improve lung function in patients with moderate to very severe chronic obstructive pulmonary disease was not more effective than alternative treatments. The 24-week AERISTO Phase IIIb trial was designed to assess the efficacy and safety of the company's disease treatment, Bevespi Aerosphere, compared with umeclidinium and vilanterol. 'The primary endpoints were peak change from baseline in FEV1 where non-inferiority and superiority were measured and change from baseline in trough FEV1 where non-inferiority was measured,' the company said. AstraZeneca said the results were 'inconsistent' with a previous trail that had demonstrated the efficacy and safety of the treatment to improve lung function. 'The efficacy and safety of Bevespi Aerosphere has been established by the Phase III PINNACLE trial programme involving more than 5,000 patients. The performance of Bevespi Aerosphere in AERISTO is inconsistent with previous data,' said Dr Colin Reisner, Head of Respiratory, Global Medicines Development. 'Bevespi Aerosphere is currently under review by the European Medicines Agency with a regulatory decision anticipated in the second half of 2018,' the company added. Story provided by StockMarketWire.com
View more share chat for Astrazeneca (AZN) >>




Astrazeneca Plc Ord Shs $0.25 home pageWebsite: Astrazeneca Plc Ord Shs $0.25
Website Description: Global Pharmaceutical company with 6700 employees across 7 sites in the UK. AstraZeneca work with the NHS, UK healthcare professionals, government and policy makers and patient groups. Market cap £65.05bn.



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.